CenTrial Logo

Clinical Trial confirms Liraglutide Helpful in Improving Quality of Life for Obese Mentally Ill


Clinical trial confirms liraglutide helpful in improving quality of life in obese mentally ill  obese

Obesity is a significant health concern, and it is especially prevalent among people with severe mental illness. Studies have shown that individuals with schizophrenia, schizoaffective disorders, or first-episode psychosis are two to three times more likely to be overweight or obese than the general population. This increased risk of obesity is associated with significant morbidity and premature mortality, making it a severe public health issue.

Liraglutide is a medication that has been approved for the treatment of obesity in the general population. It is a once-daily injectable drug that activates GLP-1 receptors, which regulate appetite and food intake. Given its effectiveness in treating obesity, there is potential for liraglutide to be used in people with severe mental illness who are struggling with obesity.

In a clinical trial, researchers evaluated the feasibility and acceptability of using liraglutide (3 mg) to treat obesity in people with severe mental illness. The study involved conducting qualitative interviews with a sample of individuals with schizophrenia, schizoaffective disorders, or first-episode psychosis who were overweight or obese and had received daily injections of liraglutide (3 mg) in a randomized controlled pilot study. Interviews were conducted with healthcare professionals to assess the feasibility of delivering the intervention in routine care.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me
The study results showed that liraglutide (3 mg) was generally well-tolerated and acceptable to the participants. Despite initial reservations about injections, most of those who completed the trial reported no challenges in the timing or administering of the injections. The participants reported feeling despondent about the weight gain associated with their prior medication, and they found that liraglutide helped them to lose weight and improve their quality of life. The healthcare professionals reported challenges with recruitment, but overall, the study was a positive experience for the participants.

In conclusion, the study suggests that liraglutide (3 mg) is an acceptable therapy for obesity in people with severe mental illness. The medication was well-tolerated with limited side effects, and the weight loss had significant quality-of-life benefits. Further research is needed to confirm these findings and assess liraglutide's long-term effectiveness in this population. Nonetheless, this study provides hope that individuals with severe mental illness who struggle with obesity may have a new treatment option to improve their health and well-being.
BMC Psychiatry, Jan-07-22

Share this article with a friend:

Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

20,000 clinical trials are seeking participants.
Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.

This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.